Cargando…
Percutaneous stent placement for the treatment of malignant biliary obstruction: nitinol versus elgiloy stents
OBJECTIVE: This study aimed to compare two self-expanding stents, a nitinol stent and an elgiloy stent, both placed percutaneously, in terms of their efficacy in palliating inoperable malignant biliary obstruction. MATERIALS AND METHODS: We retrospectively investigated 99 patients with unresectable...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Colégio Brasileiro de Radiologia e Diagnóstico por
Imagem
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396999/ https://www.ncbi.nlm.nih.gov/pubmed/28428652 http://dx.doi.org/10.1590/0100-3984.2015.0183 |
_version_ | 1783230179533914112 |
---|---|
author | Zurstrassen, Charles Edouard Bitencourt, Almir Galvão Vieira Guimaraes, Marcos Duarte Cavalcante, Aline Cristine Barbosa Santos Tyng, Chiang Jeng Amoedo, Mauricio Kauark Matsushita Junior, João Paulo Kawaoka Szklaruk, Janio Marchiori, Edson Chojniak, Rubens |
author_facet | Zurstrassen, Charles Edouard Bitencourt, Almir Galvão Vieira Guimaraes, Marcos Duarte Cavalcante, Aline Cristine Barbosa Santos Tyng, Chiang Jeng Amoedo, Mauricio Kauark Matsushita Junior, João Paulo Kawaoka Szklaruk, Janio Marchiori, Edson Chojniak, Rubens |
author_sort | Zurstrassen, Charles Edouard |
collection | PubMed |
description | OBJECTIVE: This study aimed to compare two self-expanding stents, a nitinol stent and an elgiloy stent, both placed percutaneously, in terms of their efficacy in palliating inoperable malignant biliary obstruction. MATERIALS AND METHODS: We retrospectively investigated 99 patients with unresectable malignant biliary obstruction treated with percutaneous placement of a self-expanding metallic stent at our institution between May 2007 and January 2010. Serum bilirubin and liver enzyme levels were measured before and 30 days after stenting. For all procedures using elgiloy or nitinol stents, stent occlusion and patient survival rates were calculated using Kaplan-Meyer analysis. RESULTS: All of the patients showed clinical improvement after stent placement, with no difference between the two groups. In both groups, the occlusion-free survival rate was 67% at 30 days, 37% at 90 days, 25% at 180 days, and 10% at 360 days, with no significant difference in relation to the type of stent. CONCLUSION: The two stents evaluated showed comparable efficacy for the percutaneous treatment of unresectable biliary malignancy, with good clinical results. |
format | Online Article Text |
id | pubmed-5396999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Colégio Brasileiro de Radiologia e Diagnóstico por
Imagem |
record_format | MEDLINE/PubMed |
spelling | pubmed-53969992017-04-20 Percutaneous stent placement for the treatment of malignant biliary obstruction: nitinol versus elgiloy stents Zurstrassen, Charles Edouard Bitencourt, Almir Galvão Vieira Guimaraes, Marcos Duarte Cavalcante, Aline Cristine Barbosa Santos Tyng, Chiang Jeng Amoedo, Mauricio Kauark Matsushita Junior, João Paulo Kawaoka Szklaruk, Janio Marchiori, Edson Chojniak, Rubens Radiol Bras Original Articles OBJECTIVE: This study aimed to compare two self-expanding stents, a nitinol stent and an elgiloy stent, both placed percutaneously, in terms of their efficacy in palliating inoperable malignant biliary obstruction. MATERIALS AND METHODS: We retrospectively investigated 99 patients with unresectable malignant biliary obstruction treated with percutaneous placement of a self-expanding metallic stent at our institution between May 2007 and January 2010. Serum bilirubin and liver enzyme levels were measured before and 30 days after stenting. For all procedures using elgiloy or nitinol stents, stent occlusion and patient survival rates were calculated using Kaplan-Meyer analysis. RESULTS: All of the patients showed clinical improvement after stent placement, with no difference between the two groups. In both groups, the occlusion-free survival rate was 67% at 30 days, 37% at 90 days, 25% at 180 days, and 10% at 360 days, with no significant difference in relation to the type of stent. CONCLUSION: The two stents evaluated showed comparable efficacy for the percutaneous treatment of unresectable biliary malignancy, with good clinical results. Colégio Brasileiro de Radiologia e Diagnóstico por Imagem 2017 /pmc/articles/PMC5396999/ /pubmed/28428652 http://dx.doi.org/10.1590/0100-3984.2015.0183 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Zurstrassen, Charles Edouard Bitencourt, Almir Galvão Vieira Guimaraes, Marcos Duarte Cavalcante, Aline Cristine Barbosa Santos Tyng, Chiang Jeng Amoedo, Mauricio Kauark Matsushita Junior, João Paulo Kawaoka Szklaruk, Janio Marchiori, Edson Chojniak, Rubens Percutaneous stent placement for the treatment of malignant biliary obstruction: nitinol versus elgiloy stents |
title | Percutaneous stent placement for the treatment of malignant biliary
obstruction: nitinol versus elgiloy stents |
title_full | Percutaneous stent placement for the treatment of malignant biliary
obstruction: nitinol versus elgiloy stents |
title_fullStr | Percutaneous stent placement for the treatment of malignant biliary
obstruction: nitinol versus elgiloy stents |
title_full_unstemmed | Percutaneous stent placement for the treatment of malignant biliary
obstruction: nitinol versus elgiloy stents |
title_short | Percutaneous stent placement for the treatment of malignant biliary
obstruction: nitinol versus elgiloy stents |
title_sort | percutaneous stent placement for the treatment of malignant biliary
obstruction: nitinol versus elgiloy stents |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396999/ https://www.ncbi.nlm.nih.gov/pubmed/28428652 http://dx.doi.org/10.1590/0100-3984.2015.0183 |
work_keys_str_mv | AT zurstrassencharlesedouard percutaneousstentplacementforthetreatmentofmalignantbiliaryobstructionnitinolversuselgiloystents AT bitencourtalmirgalvaovieira percutaneousstentplacementforthetreatmentofmalignantbiliaryobstructionnitinolversuselgiloystents AT guimaraesmarcosduarte percutaneousstentplacementforthetreatmentofmalignantbiliaryobstructionnitinolversuselgiloystents AT cavalcantealinecristinebarbosasantos percutaneousstentplacementforthetreatmentofmalignantbiliaryobstructionnitinolversuselgiloystents AT tyngchiangjeng percutaneousstentplacementforthetreatmentofmalignantbiliaryobstructionnitinolversuselgiloystents AT amoedomauriciokauark percutaneousstentplacementforthetreatmentofmalignantbiliaryobstructionnitinolversuselgiloystents AT matsushitajuniorjoaopaulokawaoka percutaneousstentplacementforthetreatmentofmalignantbiliaryobstructionnitinolversuselgiloystents AT szklarukjanio percutaneousstentplacementforthetreatmentofmalignantbiliaryobstructionnitinolversuselgiloystents AT marchioriedson percutaneousstentplacementforthetreatmentofmalignantbiliaryobstructionnitinolversuselgiloystents AT chojniakrubens percutaneousstentplacementforthetreatmentofmalignantbiliaryobstructionnitinolversuselgiloystents |